生物标志物在卵巢癌复发早期检测中的作用。
Role of biomarkers for early detection of ovarian cancer recurrence.
作者信息
Giampaolino Pierluigi, Foreste Virginia, Della Corte Luigi, Di Filippo Claudia, Iorio Giuseppe, Bifulco Giuseppe
机构信息
Department of Public Health, School of Medicine, University of Naples Federico II, Naples, Italy.
Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.
出版信息
Gland Surg. 2020 Aug;9(4):1102-1111. doi: 10.21037/gs-20-544.
Ovarian cancer is frequently diagnosed at an advanced stage and a fraction of these patients fail to respond to primary therapy and relapses in 70% of cases. On account of the high recurrence probability and the poor outcomes after recurrence, there is an urgent need to predict progression as early as possible and thus found the strategies to detect and prevent a recurrence. Considering that biomarkers have contributed to the management of ovarian cancer by distinguishing benign and malignant pelvic masses and monitoring response to treatment, in this review, we aim to discuss the latest evidence reported in the literature about the use of biomarkers to detect OC recurrence. In detail, we summarized all the evidence of the most quoted biomarkers like HE4, osteopontin, mesothelin (MSLN), Folate receptor α (FOLR1), paraneoplastic antigens, miRNA, cancer stem cells (CSCs) and a combination of them to evaluate their role as prognostic biomarkers for ovarian cancer recurrence.
卵巢癌常常在晚期才被诊断出来，其中一部分患者对初始治疗无反应，70%的病例会复发。鉴于复发概率高且复发后的预后不佳，迫切需要尽早预测病情进展，从而找到检测和预防复发的策略。考虑到生物标志物通过区分良性和恶性盆腔肿块以及监测治疗反应，为卵巢癌的管理做出了贡献，在本综述中，我们旨在讨论文献中报道的关于使用生物标志物检测卵巢癌复发的最新证据。详细地说，我们总结了最常被引用的生物标志物的所有证据，如人附睾蛋白4（HE4）、骨桥蛋白、间皮素（MSLN）、叶酸受体α（FOLR1）、副肿瘤抗原、微小RNA（miRNA）、癌症干细胞（CSC）以及它们的组合，以评估它们作为卵巢癌复发预后生物标志物的作用。
Zotero 插件